Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 7 |
| List of Tables | 7 | 1 |
| List of Figures | 8 | 1 |
| Introduction | 9 | 1 |
| Global Markets Direct Report Coverage | 9 | 1 |
| Fibroblast Growth Factor Receptor 3 (Tyrosine Kinase JTK4 or Hydroxyaryl Protein Kinase or CD333 or FGFR3 or EC 2.7.10.1) Overview | 10 | 1 |
| Therapeutics Development | 11 | 5 |
| Fibroblast Growth Factor Receptor 3 (Tyrosine Kinase JTK4 or Hydroxyaryl Protein Kinase or CD333 or FGFR3 or EC 2.7.10.1) Products under Development by Stage of Development | 11 | 1 |
| Fibroblast Growth Factor Receptor 3 (Tyrosine Kinase JTK4 or Hydroxyaryl Protein Kinase or CD333 or FGFR3 or EC 2.7.10.1) Products under Development by Therapy Area | 12 | 1 |
| Fibroblast Growth Factor Receptor 3 (Tyrosine Kinase JTK4 or Hydroxyaryl Protein Kinase or CD333 or FGFR3 or EC 2.7.10.1) Products under Development by Indication | 13 | 3 |
| Fibroblast Growth Factor Receptor 3 (Tyrosine Kinase JTK4 or Hydroxyaryl Protein Kinase or CD333 or FGFR3 or EC 2.7.10.1) Pipeline Products Glance | 16 | 2 |
| Late Stage Products | 16 | 1 |
| Early Stage Products | 17 | 1 |
| Fibroblast Growth Factor Receptor 3 (Tyrosine Kinase JTK4 or Hydroxyaryl Protein Kinase or CD333 or FGFR3 or EC 2.7.10.1) Products under Development by Companies | 18 | 12 |
| Fibroblast Growth Factor Receptor 3 (Tyrosine Kinase JTK4 or Hydroxyaryl Protein Kinase or CD333 or FGFR3 or EC 2.7.10.1) Products under Development by Universities/Institutes | 30 | 2 |
| Fibroblast Growth Factor Receptor 3 (Tyrosine Kinase JTK4 or Hydroxyaryl Protein Kinase or CD333 or FGFR3 or EC 2.7.10.1) Therapeutics Assessment | 32 | 7 |
| Assessment by Monotherapy/Combination Products | 32 | 1 |
| Assessment by Mechanism of Action | 33 | 2 |
| Assessment by Route of Administration | 35 | 2 |
| Assessment by Molecule Type | 37 | 2 |
| Fibroblast Growth Factor Receptor 3 (Tyrosine Kinase JTK4 or Hydroxyaryl Protein Kinase or CD333 or FGFR3 or EC 2.7.10.1) Companies Involved in Therapeutics Development | 39 | 28 |
| AB Science SA | 39 | 2 |
| Advenchen Laboratories, LLC | 41 | 1 |
| Amgen Inc. | 42 | 1 |
| ArQule, Inc. | 43 | 1 |
| Astellas Pharma Inc. | 44 | 1 |
| AstraZeneca Plc | 45 | 1 |
| AVEO Pharmaceuticals, Inc. | 46 | 1 |
| Bayer AG | 47 | 1 |
| Boehringer Ingelheim GmbH | 48 | 1 |
| Bristol-Myers Squibb Company | 49 | 1 |
| CASI Pharmaceuticals Inc. | 50 | 1 |
| Celon Pharma Sp. z o.o. | 51 | 1 |
| Debiopharm International SA | 52 | 1 |
| Eddingpharm | 53 | 1 |
| Eisai Co., Ltd. | 54 | 2 |
| Eli Lilly and Company | 56 | 1 |
| Evotec AG | 57 | 1 |
| Hutchison MediPharma Limited | 58 | 1 |
| Incyte Corporation | 59 | 1 |
| Johnson &Johnson | 60 | 1 |
| Les Laboratoires Servier SAS | 61 | 1 |
| Merck KGaA | 62 | 1 |
| Novartis AG | 63 | 2 |
| Principia Biopharma Inc. | 65 | 1 |
| Vichem Chemie Research Ltd. | 66 | 1 |
| Fibroblast Growth Factor Receptor 3 (Tyrosine Kinase JTK4 or Hydroxyaryl Protein Kinase or CD333 or FGFR3 or EC 2.7.10.1) Drug Profiles | 67 | 78 |
| ARQ-087 Drug Profile | 67 | 2 |
| ASP-5878 Drug Profile | 69 | 1 |
| AV-370 Drug Profile | 70 | 1 |
| AZD-4547 Drug Profile | 71 | 2 |
| B-701 Drug Profile | 73 | 1 |
| BAY-1163877 Drug Profile | 74 | 1 |
| BMS-986036 Drug Profile | 75 | 1 |
| CPL-043 Drug Profile | 76 | 1 |
| Debio-1347 Drug Profile | 77 | 2 |
| Drugs to Inhibit FGFR3 for Bladder Cancer Drug Profile | 79 | 1 |
| E-7090 Drug Profile | 80 | 1 |
| EDP-317 Drug Profile | 81 | 1 |
| ENMD-2076 Drug Profile | 82 | 6 |
| erdafitinib Drug Profile | 88 | 2 |
| HMPL-453 Drug Profile | 90 | 1 |
| INCB-54828 Drug Profile | 91 | 1 |
| infigratinib Drug Profile | 92 | 2 |
| lenvatinib mesylate Drug Profile | 94 | 11 |
| lucitanib Drug Profile | 105 | 3 |
| LY-2874455 Drug Profile | 108 | 1 |
| masitinib Drug Profile | 109 | 14 |
| nintedanib Drug Profile | 123 | 8 |
| pazopanib hydrochloride Drug Profile | 131 | 6 |
| pazopanib hydrochloride + pembrolizumab Drug Profile | 137 | 1 |
| PRN-1371 Drug Profile | 138 | 1 |
| Recombinant Protein to Agonize FGFR for Type 2 Diabetes Drug Profile | 139 | 1 |
| Recombinant Proteins to Agonize FGFR for Metabolic Disorders Drug Profile | 140 | 1 |
| S-49076 Drug Profile | 141 | 1 |
| Small Molecules to Antagonize Pan FGFR for Oncology Drug Profile | 142 | 1 |
| sprifermin Drug Profile | 143 | 2 |
| Fibroblast Growth Factor Receptor 3 (Tyrosine Kinase JTK4 or Hydroxyaryl Protein Kinase or CD333 or FGFR3 or EC 2.7.10.1) Dormant Projects | 145 | 4 |
| Fibroblast Growth Factor Receptor 3 (Tyrosine Kinase JTK4 or Hydroxyaryl Protein Kinase or CD333 or FGFR3 or EC 2.7.10.1) Discontinued Products | 149 | 3 |
| Fibroblast Growth Factor Receptor 3 (Tyrosine Kinase JTK4 or Hydroxyaryl Protein Kinase or CD333 or FGFR3 or EC 2.7.10.1) Featured News &Press Releases | 152 | 15 |
| Jun 06, 2016: AB Science announces that Rapporteurs appointed by the EMA have recommended the filing of masitinib in ALS for conditional marketing authorization | 152 | 1 |
| Jun 06, 2016: Principia Biopharma Announces Presentation of Initial Clinical Data on PRN1371 at 2016 American Society of Clinical Oncology Annual Meeting | 152 | 1 |
| Jun 01, 2016: CASI Pharmaceuticals Announces Poster Presentation At ASCO On ENMD-2076 In Patients With Ovarian Clear Cell Carcinoma | 153 | 1 |
| May 30, 2016: AB Science will Present Phase 3 Data in Severe Systemic Mastocytosis at the International 21St Congress of the European Hematology Association | 153 | 1 |
| May 24, 2016: Eisai To Present on Lenvima at 52nd Annual Meeting of the American Society of Clinical Oncology | 154 | 1 |
| May 16, 2016: U.S. FDA Approves additional indication for Eisai anti cancer agent LENVIMA in Combination with Everolimus as Treatment for Advanced Renal Cell Carcinoma | 155 | 1 |
| May 16, 2016: New Presentations at ATS 2016 Reinforce OFEV (nintedanib) Efficacy, Safety and Tolerability Across Range of Patients with idiopathic pulmonary fibrosis | 156 | 2 |
| May 12, 2016: CASI Pharmaceuticals Receives Approval From CFDA To Conduct Phase 2 Clinical Trial With ENMD-2076 For Fibrolamellar Carcinoma (FLC) | 158 | 1 |
| May 09, 2016: LUME-Meso trial enrols first patient: Boehringer Ingelheim s new pivotal study investigating nintedanib for the treatment of malignant pleural mesothelioma | 158 | 1 |
| May 02, 2016: AB Science has submitted to EMA the marketing authorization application for Masitinib in the Treatment of Severe Systemic Mastocytosis | 159 | 1 |
| Apr 20, 2016: Eisai Announces Non-Clinical Research Findings At Aacr 107Th Annual Meeting Regarding Combination Of Anticancer Agent Lenvatinib With Everolimus | 160 | 1 |
| Apr 15, 2016: Debiopharm International announces presentation at AACR of non-clinical data relating to its targeted investigational compound Debio 1347/CH5183284, a selective FGFR 1,2,3 inhibitor | 160 | 1 |
| Apr 12, 2016: Highly Anticipated New Treatment Option Now Available for Canadians with Select Type of Thyroid Cancer | 161 | 1 |
| Apr 11, 2016: Masitinib in Amyotrophic Lateral Sclerosis (ALS) | 162 | 3 |
| Apr 06, 2016: AB Science Will Host Live Webcast On Phase 3 Interim Analysis In ALS On 8 April 2016, | 165 | 2 |
| Appendix | 167 | 2 |
| Methodology | 167 | 1 |
| Coverage | 167 | 1 |
| Secondary Research | 167 | 1 |
| Primary Research | 167 | 1 |
| Expert Panel Validation | 167 | 1 |
| Contact Us | 167 | 1 |
| Disclaimer | 168 | 1 |